Key clinical point: Transarterial chemoembolization (TACE) via transradial access (TRA) leads to improved patient satisfaction along with similar procedural variables and safety compared with TACE via transfemoral access (TFA) in patients with hepatocellular carcinoma (HCC).
Major finding: In the TACE-TRA vs TACE-TFA group a significantly higher proportion of patients preferred the current access for their next procedure (90.8% vs 24.6%; P < .001), although between-group procedural variables (such as procedure time and length of hospital stay; all P > .05) and the incidence and severity of adverse events (all P > .05) were similar.
Study details: This single-center prospective randomized controlled trial included 130 patients with HCC who underwent TACE for the first time either via TRA (n = 65) or TFA (n = 65).
Disclosures: This study was sponsored by the Beijing Hope Run Special Fund of the Cancer Foundation of China. The authors declared no conflicts of interest.
Source: Zhang X et al. Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized trial. Eur Radiol. 2022 (Aug 26). Doi: 10.1007/s00330-022-09038-1
